12 results on '"Hendlisz A"'
Search Results
2. Neoadjuvant chemotherapy for early-stage colon cancer
- Author
-
Audisio, Alessandro, Fazio, Roberta, Daprà, Valentina, Assaf, Irene, Hendlisz, Alain, and Sclafani, Francesco
- Published
- 2024
- Full Text
- View/download PDF
3. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
- Author
-
Akin Telli, Tugba, primary, Bregni, Giacomo, additional, Vanhooren, Michele, additional, Saude Conde, Rita, additional, Hendlisz, Alain, additional, and Sclafani, Francesco, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
- Author
-
Tugba Akin Telli, Giacomo Bregni, Michele Vanhooren, Rita Saude Conde, Alain Hendlisz, and Francesco Sclafani
- Subjects
Oncology ,Pyridines ,Phenylurea Compounds ,Tumor Microenvironment ,Humans ,Microsatellite Instability ,Radiology, Nuclear Medicine and imaging ,General Medicine ,Colorectal Neoplasms ,DNA Mismatch Repair ,Immune Checkpoint Inhibitors ,Microsatellite Repeats - Abstract
Immune checkpoint inhibitors (ICIs) have marked a new era of cancer treatment, showing remarkable efficacy in a wide range of solid malignancies. In colorectal cancer (CRC), however, the therapeutic potential of ICIs is limited to the small group (≈5%) of patients with mismatch repair deficient (dMMR)/high microsatellite instable (MSI-H) tumours, which are characterised by high mutational/neo-antigen burden, and an inflammatory tumour microenvironment with abundant tumour-infiltrating lymphocytes. Over the last few years, research has focused on immuno-modulatory strategies that could overcome the inherent resistance to ICIs that is observed in the vast group (≈95%) of patients with mismatch repair proficient (pMMR)/microsatellite stable (MSS) tumours. Among these, the combination of ICIs with multi-kinase inhibitors has gained traction in preclinical studies and clinical trials. Thanks to their multiple targets and mechanisms of action, generally involving key cancer pathways such as oncogenesis, angiogenesis, metastasis, and tumour immunity, these agents can exert synergistic effects with ICIs, eventually turning inherently cold cancers into hot tumours, that can be efficiently recognised and targeted by an activated immune system. Regorafenib is routinely used for chemorefractory CRC with limited efficacy. Preliminary evidence, however, suggests that this multi-kinase inhibitor could be an optimal combination partner for ICIs. In this review article, we explain the biological rationale underlying the synergism between regorafenib and ICIs, discuss the available clinical data in CRC, and take a glance into future perspectives by presenting ongoing trials and possible research developments in this setting.
- Published
- 2022
5. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
- Author
-
Alain Hendlisz, Luigi Moretti, Francesco Sclafani, Andrea Pretta, Amélie Deleporte, Fortunato Ciardiello, Teresa Troiani, A.M. Bali, Emilio Francesco Giunta, Gabriel Liberale, Giacomo Bregni, Giunta, E. F., Bregni, G., Pretta, A., Deleporte, A., Liberale, G., Bali, A. M., Moretti, L., Troiani, T., Ciardiello, F., Hendlisz, A., and Sclafani, F.
- Subjects
0301 basic medicine ,medicine.medical_specialty ,RAPIDO ,Organoplatinum Compounds ,Colorectal cancer ,medicine.medical_treatment ,Total neoadjuvant therapy ,Locally advanced ,Leucovorin ,Consolidation chemotherapy ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Stage (cooking) ,Rectal cancer ,Intensive care medicine ,Imagerie médicale, radiologie, tomographie ,Neoadjuvant therapy ,Capecitabine ,Neoplasm Staging ,Randomized Controlled Trials as Topic ,Antineoplastic Combined Chemotherapy Protocol ,PRODIGE 23 ,business.industry ,Rectal Neoplasms ,Organoplatinum Compound ,Induction chemotherapy ,Consolidation Chemotherapy ,General Medicine ,Chemoradiotherapy ,medicine.disease ,Neoadjuvant Therapy ,Radiation therapy ,Cancérologie ,Oxaliplatin ,030104 developmental biology ,Oncology ,Clinical Trials, Phase III as Topic ,030220 oncology & carcinogenesis ,Fluorouracil ,business ,Human - Abstract
A few months ago, results from two randomised phase III trials of total neoadjuvant therapy (TNT) in locally advanced rectal cancer were presented (RAPIDO and PRODIGE 23), consistently showing better short- and long-term outcomes with TNT as compared with standard neoadjuvant long-course chemoradiotherapy (CRT) or short-course radiotherapy (SCRT). These results represent corroborating evidence in support of a practice that many centres had already implemented based on promising preliminary data. Also, they provide new, high-level evidence to endorse TNT as a new management option in the treatment algorithm of stage II-III rectal cancer in those centres where CRT and SCRT have long remained the only accepted standard neoadjuvant treatments. Having two consistently positive trials is certainly reassuring regarding the potential of TNT as a general treatment approach. Nevertheless, substantial differences between these trials pose important challenges in relation to the generalisability and applicability of their results, and translation of the same into practical clinical recommendations. In this article, we address a number of key questions that the RAPIDO and PRODIGE 23 trials have raised among the broad community of gastrointestinal oncologists, proposing an interpretation of the data that may help the decision making, and highlighting grey areas that warrant further investigation., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2021
6. Imaging and clinical correlates with regorafenib in metastatic colorectal cancer
- Author
-
David Cunningham, Nazim Serdar Turhal, Salvatore Siena, Alain Hendlisz, Tara Seery, Sun Young Kim, Stefano Cascinu, Eiji Oki, Khurum Khan, Christophe Tournigand, Lin Shen, Khan, K., Cascinu, S., Cunningham, D., Kim, S. -Y., Oki, E., Seery, T., Shen, L., Siena, S., Tournigand, C., Turhal, N. S., and Hendlisz, A.
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Positron emission tomography ,Colorectal cancer ,medicine.drug_class ,Angiogenesis ,Pyridines ,Tyrosine-kinase inhibitor ,Metastasis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Magnetic resonance imaging ,Internal medicine ,Regorafenib ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Metastasis ,Imagerie médicale, radiologie, tomographie ,Computed tomography ,Protein Kinase Inhibitors ,Randomized Controlled Trials as Topic ,medicine.diagnostic_test ,Neovascularization, Pathologic ,business.industry ,Metastatic colorectal cancer ,Phenylurea Compounds ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,Cancérologie ,030104 developmental biology ,chemistry ,Response Evaluation Criteria in Solid Tumors ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,business ,Colorectal Neoplasms ,Tomography, X-Ray Computed - Abstract
In colorectal cancer (CRC), imaging is important in determining tumor stage, selecting treatment strategies, and in assessing response to therapy. However, some challenges remain with established imaging techniques, such as computed tomography, and with some commonly used response criteria, such as Response Evaluation Criteria in Solid Tumors, which measures change in size of several target lesions instead of change in tumor morphology or metabolic function. In addition, these assessments are not typically conducted until after 8 weeks of treatment, meaning that potential non-responders are often not identified in a timely manner. Regorafenib, an oral tyrosine kinase inhibitor indicated for the treatment of metastatic CRC, blocks the activity of several protein kinases involved in angiogenesis, oncogenesis, metastasis, and tumor immunity. Timely differentiation of regorafenib responders from non-responders using appropriate imaging techniques that recognize not only changes in tumor size but also changes in tumor density or vasculature, may reduce unnecessary drug-related toxicity in patients who are unlikely to respond to treatment. This review discusses the latest developments in computed tomography, magnetic resonance imaging, and positron emission tomography tumor imaging modalities, and how these aid in identifying patients with metastatic CRC who are responders or non-responders to regorafenib treatment., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2020
7. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
- Author
-
Giunta, E.F., primary, Bregni, G., additional, Pretta, A., additional, Deleporte, A., additional, Liberale, G., additional, Bali, A.M., additional, Moretti, L., additional, Troiani, T., additional, Ciardiello, F., additional, Hendlisz, A., additional, and Sclafani, F., additional
- Published
- 2021
- Full Text
- View/download PDF
8. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice
- Author
-
Gabriel Liberale, T. Akin Telli, Giacomo Bregni, Stéphane Holbrechts, Silvia Camera, A.M. Bali, Alain Hendlisz, Luigi Moretti, Amélie Deleporte, and Francesco Sclafani
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Colorectal cancer ,Adjuvant chemotherapy ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Rectal cancer ,Intensive care medicine ,Chemotherapy ,business.industry ,Rectal Neoplasms ,Standard treatment ,Patient Selection ,General Medicine ,medicine.disease ,Oxaliplatin ,Radiation therapy ,Clinical trial ,Cancérologie ,030104 developmental biology ,Oncology ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,business ,Adjuvant ,Fluoropyrimidine ,medicine.drug - Abstract
While adjuvant chemotherapy is an established treatment for pathological stage II and especially stage III colon cancer, its role in the multimodal management of rectal cancer remains controversial. As a result, there is substantial variation in the use of this treatment in clinical practice. Even among centres and physicians who consider adjuvant chemotherapy as a standard treatment, notable heterogeneity exists with regard to patient selection criteria and chemotherapy regimens. The controversy around this topic is confirmed by the lack of full consensus among national and international clinical guidelines. While most of the clinical trials do not support the contention that adjuvant chemotherapy may improve survival outcomes if pre-operative (chemo)radiotherapy is also given, these suffer from many limitations that preclude drawing definitive conclusions. Nevertheless, in the era of evidence-based medicine, physicians should be guided by the available data and refrain from extrapolating results of adjuvant colon cancer trials to inform treatment decisions for rectal cancer. Patients should be informed of the evidence gap, be given the opportunity to carefully discuss pros and cons of all the possible management options and be empowered in the decision making. In this article we review the available evidence on adjuvant chemotherapy for rectal cancer and propose a risk-adapted decisional algorithm that largely relies on informed patient preferences., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2019
9. Imaging and clinical correlates with regorafenib in metastatic colorectal cancer
- Author
-
Khan, Khurum, primary, Cascinu, Stefano, additional, Cunningham, David, additional, Kim, Sun-Young, additional, Oki, Eiji, additional, Seery, Tara, additional, Shen, Lin, additional, Siena, Salvatore, additional, Tournigand, Christophe, additional, Turhal, Nazim Serdar, additional, and Hendlisz, Alain, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice
- Author
-
Bregni, G., primary, Akin Telli, T., additional, Camera, S., additional, Deleporte, A., additional, Moretti, L., additional, Bali, A.M., additional, Liberale, G., additional, Holbrechts, S., additional, Hendlisz, A., additional, and Sclafani, F., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines
- Author
-
Bregni, G., primary, Akin Telli, T., additional, Camera, S., additional, Baratelli, C., additional, Shaza, L., additional, Deleporte, A., additional, Moretti, L., additional, Bali, M.A., additional, Liberale, G., additional, Hendlisz, A., additional, and Sclafani, F., additional
- Published
- 2020
- Full Text
- View/download PDF
12. Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines
- Author
-
Maria Antonietta Bali, Giacomo Bregni, Alain Hendlisz, Silvia Camera, Chiara Baratelli, Gabriel Liberale, Leila Shaza, Amélie Deleporte, Francesco Sclafani, T. Akin Telli, and Luigi Moretti
- Subjects
Clinical guidelines ,0301 basic medicine ,medicine.medical_specialty ,Colorectal cancer ,JSCCR ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Complete Agreement ,Rectal cancer ,Imagerie médicale, radiologie, tomographie ,NCCN ,Ontario ,Evidence-Based Medicine ,Rectal Neoplasms ,business.industry ,Australia ,General Medicine ,Evidence-based medicine ,ESMO ,medicine.disease ,Professional Practice Gaps ,Cancérologie ,Clinical Practice ,030104 developmental biology ,Oncology ,Clinical question ,030220 oncology & carcinogenesis ,Family medicine ,Practice Guidelines as Topic ,business - Abstract
Background: While the management of nonmetastatic and oligometastatic rectal cancer has rapidly evolved over the last few decades, many grey areas and highly debated topics remain that foster significant variation in clinical practice. We aimed to identify controversial points and evidence gaps in this disease setting by systematically comparing recommendations from national and international clinical guidelines. Methods: Twenty-six clinical questions reflecting practical challenges in the routine management of nonmetastatic and oligometastatic rectal cancer patients were selected. Recommendations from the ESMO, NCCN, JSCCR, Australian and Ontario guidelines were extrapolated and compared using a 4-tier classification system (i.e. identical/very similar, similar, slightly different, different). Overall agreement between guidelines (i.e. substantial/complete disagreement, partial disagreement, partial agreement, substantial/complete agreement) was assessed for each clinical question and compared against the highest level of available evidence by using the χ2 statistic test. Results: Guidelines were in substantial/complete agreement, partial agreement, partial disagreement, and substantial/complete disagreement for 8 (30.8%), 2 (7.7%), 7 (26.9%), and 9 (34.6%) clinical questions, respectively. High level of evidence supported clinical recommendations in 3/10 cases (30%) where guidelines were in agreement and in 10/16 cases (62.5%) where guidelines were in disagreement (χ2 = 2.6, p = 0.106). Agreement was frequently reached for questions regarding diagnosis, staging, and radiology/pathology pro-forma reporting, while disagreement characterised most of the treatment-related topics. Conclusions: Substantial variation exists across clinical guidelines in the recommendations for the management of nonmetastatic and oligometastatic rectal cancer. This variation is only partly explained by the lack of supporting, high-level evidence., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.